Tilray Brands (TLRY) Capital Expenditures (2017 - 2025)
Tilray Brands (TLRY) posted Capital Expenditures of $6.3 million for Q2 2025, down 56.08% on a QoQ basis from $14.4 million in Q1 2025, and down 34.8% year-over-year from $9.7 million in Q2 2024.
Tilray Brands (TLRY) Capital Expenditures (2017 - 2025) Analysis & Trends
Tilray Brands' Capital Expenditures history runs 9 years deep, the most recent figure standing at $6.3 million for Q2 2025.
- Quarterly Capital Expenditures fell 34.8% year-over-year to $6.3 million in Q2 2025, while the trailing twelve-month figure through May 2025 was $32.9 million (up 12.54% YoY) and the FY2025 annual result came in at $32.9 million, up 12.54% from the prior year.
- Capital Expenditures was $6.3 million for Q2 2025 at Tilray Brands, down from $14.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $16.3 million in Q3 2021 and bottomed at $857000.0 in Q1 2023.
- A 5-year average of $7.2 million and a median of $5.9 million in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures sank 89.78% — and 2024, when it soared 1011.79%.
- Tilray Brands' Capital Expenditures stood at $7.5 million in 2021, then tumbled by 39.83% to $4.5 million in 2022, then rose by 29.14% to $5.9 million in 2023, then fell by 7.22% to $5.4 million in 2024, then rose by 16.46% to $6.3 million in 2025.
- Business Quant data shows TLRY's Capital Expenditures at $6.3 million in Q2 2025, $14.4 million in Q1 2025, and $5.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | 6.33 Mn |
| May 31, 2025 | 6.33 Mn |
| Feb 28, 2025 | 14.41 Mn |
| Feb 28, 2025 | 14.41 Mn |
| Nov 30, 2024 | 5.44 Mn |
| Nov 30, 2024 | 5.44 Mn |
| Aug 31, 2024 | 6.74 Mn |
| Aug 31, 2024 | 6.74 Mn |
| May 31, 2024 | 9.71 Mn |
| May 31, 2024 | 9.71 Mn |
| Feb 29, 2024 | 9.53 Mn |
| Feb 29, 2024 | 9.53 Mn |
| Nov 30, 2023 | 5.86 Mn |
| Nov 30, 2023 | 5.86 Mn |
| Aug 31, 2023 | 4.15 Mn |
| Aug 31, 2023 | 4.15 Mn |
| May 31, 2023 | 12.41 Mn |
| May 31, 2023 | 12.41 Mn |
| Feb 28, 2023 | 857,000.00 |
| Feb 28, 2023 | 857,000.00 |